David P. Meeker
Principal executive officer pay for David P. Meeker, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
RHYTHM PHARMACEUTICALS, INC. (RYTM) FY2021–FY2025
Beat peersTSR 972% vs peer group -6% over FY2021–FY2025
Turnaround$100 invested moved from behind the peer group ($33.57 vs $100.02) to ahead ($360.00 vs $93.71) over FY2021–FY2025
Aligned: paid up as stock roseCAP -$10,017,699→$54,157,885 while $100 invested went $33.57→$360.00
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2021 | $6.5M | -$10.0M |
| FY2022 | $3.3M | $24.1M |
| FY2023 | $7.2M | $19.0M |
| FY2024 | $14.7M | $18.7M |
| FY2025 | $17.5M | $54.2M |
The company's "$100 invested" index ran $33.57 at FY2021 → $360.00 by FY2025 — an annualized return of 81.0%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 81.0%/yr at RYTM ( FY2021–FY2025). See the CEO track-record ranking for context.